Please assess the completion status of the following clinical trial:

Trial Title: Using Imaging to Assess Effects of THC on Brain Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria General~1. Men and women aged 18-55 years, inclusive; (for Phase 2B: men and women aged 21-55 years, inclusive)~2. Competent and willing to provide written informed consent;~3. Able to communicate in English language.~4. Regular, at least monthly, marijuana use, confirmed by positive urine screen for THC~   Additional Inclusion Criteria For Phase 2B:~5. Past consumption of at least two alcoholic beverages in one occasion.~6. Past co-consumption of alcohol and THC at least once in lifetime with no serious adverse effects.~7. Weigh more than 100 lbs.~Exclusion Criteria:~General (Phase 2A, 2B 3)~1. Any unstable, serious medical illness, or cardiovascular disease or events.~2. New or unstable psychiatric symptoms, schizophrenia, or bipolar I disorder,~3. Diabetes, cirrhosis, renal failure, Hepatitis C, HIV,~4. History of syncope without an identified situational stressor, migraines \>1x/month, head injury with prolonged unconsciousness (\> 24 hours);~5. Allergy to sesame oil (contained in Marinol pills) or Marinol capsules~6. Daily use of benzodiazepines or barbiturates, antihistamines, atropine, scopolamine, or other strong anticholinergic agents;~7. Current pregnancy or lactation, or trying to become pregnant (confirmed by urine pregnancy test)~8. In the opinion of the investigator, not able to safely participate in this study.~   Additional Exclusion Criteria For Phase 2B:~9. Currently seeking treatment, in treatment, or in recovery from an alcohol use disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Phase 2A (Type: EXPERIMENTAL): In a double-blind placebo-controlled, random order cross-over study of single dose dronabinol, participants received dronabinol or identical placebo on two separate study visits in randomized order.
- Phase 2B (Type: EXPERIMENTAL): In a randomized, double-blind, 4-treatment, 4-period, crossover study with THC or placebo administration and ethanol or placebo administration, participants were randomly assigned to 1 of 4 sequences and received each of the following treatments: placebo dronabinol + placebo ethanol, placebo dronabinol + ethanol, dronabinol + placebo ethanol, \& dronabinol + ethanol.

Based on this trial design, predict the completion outcome and termination type (if applicable).